Actinium-225 PSMA Therapy with PET Imaging — Johns Hopkins Medicine StandardsHow it works
How Much Does Actinium-225 Therapy Cost in Turkey in AUD?
Actinium-225 therapy in Turkey typically costs between AUD $27,200 and AUD $44,500 per cycle. Final expenses depend on the medication regimen, imaging needs, and the number of cycles required for treatment. High-tier Turkish packages often include PET scans, renal scintigraphy, oncology consultations, and airport transfers.
- Single treatment cycle: AUD $27,200 to AUD $44,500 including basic blood diagnostics and medication.
- Diagnostic imaging: typically adds 10–15% if PET-CT scans are not bundled into the package.
- Specialised nuclear medicine: may cost 20% more for neuroendocrine cancer protocols compared to prostate cancer.
- Extended stays: while transfers are included, patients should budget for local accommodation near Istanbul clinics.
Bookimed Expert Insight: Choosing a clinic with international affiliations provides American or European standards at Turkish prices. Anadolu Medical Center maintains a strategic partnership with Johns Hopkins Medicine and offers packages starting around A$32,100. These comprehensive bundles include essential MAG-3 renal scintigraphy and DOTA or PSMA PET scans. Specialists like Professor Kezban Berberoglu, who trained at Johns Hopkins, provide the high level of expertise Australians expect.
| Turkey | Thailand | |
|---|---|---|
| Actinium-225 Therapy | from AUD $27,200 | ≈ AUD $35,600 |
Best Actinium-225 Therapy Clinics in Turkey for Australians: 5 Verified Options and AUD Prices
Actinium-225 PSMA Therapy with PET Imaging — Johns Hopkins Medicine Standards
Actinium-225 Therapy with DOTA PET for Neuroendocrine Cancer — Johns Hopkins Standards
Actinium-225 PSMA Therapy for Prostate Cancer at JCI & ESMO-Accredited Center
Actinium-225 Therapy for Neuroendocrine Cancer at JCI & ESMO-Accredited Center
Actinium-225 (Ac-225) Targeted Radionuclide TherapyActinium-225 Therapy Overview in Turkey
- Targeted therapy - from AUD $4,453This therapy focuses on specific cancer cells, curbing their growth and spread with fewer side effects.
- Lutetium-177 therapy - from AUD $7,421This therapy uses radioactive particles to kill cancer cells, offering precise, effective treatment with fewer side effects.
- Bookimed deposit: $200 or €200.
- Clinic deposit: Pay a set percentage in advance.
Our Doctors
View all Doctors
Kezban Berberoglu
Dr. Kezban Berberoglu is a professor of nuclear medicine at Anadolu Medical Center in Istanbul. She completed training at the Johns Hopkins University School of Medicine in Baltimore. Dr. Berberoglu specializes in nuclear oncology and nuclear cardiology. She treats thyroid and prostate cancers using radioisotope therapies. She is a member of the European Association of Nuclear Medicine.
- Performs Lutetium-177 and Actinium-225 therapies for oncology patients.
- Expert in PET-CT imaging using Gallium 68 for oncology cases.
- Member of the Turkish Nuclear Medicine Association cardiology work group.
- Works at an MTQUA Top 10 world hospital affiliated with Johns Hopkins.

Cuneyt Turkmen
Dr. Cuneyt Turkmen is a nuclear medicine specialist at Memorial Şişli Hospital in Istanbul. He has published over 80 scientific papers on oncology and imaging. Dr. Turkmen completed a professional fellowship at Sahlgrenska University Hospital in Sweden. He focuses on targeted radionuclide therapy for liver, prostate, and thyroid cancers.
- Performs radioembolization and Lutetium-177 therapy for advanced cancer cases.
- Expertise in Actinium-225 radiation and Amyloid PET scans.
- Member of the European Association of Nuclear Medicine.
- Works at a JCI-accredited hospital, the first in Turkey to reach this standard.

Abdullah Sakin
Prof. Dr. Abdullah Sakin is a professor of medical oncology. He treats solid tumors, including lung, breast, gastrointestinal, genitourinary, gynecologic, head and neck cancers, and melanoma.
He delivers personalized, evidence-based care. His treatments include chemotherapy, targeted therapy, immunotherapy, hormone therapy, and precision oncology. He has authored more than 200 scientific publications and takes part in international clinical research. This work advances patient-centered cancer care.

Gul Alco
Prof. Dr. Gül Alço is a radiation oncologist with about 27 years of experience. She treats breast, lung, prostate, gastrointestinal, gynecologic, central nervous system, head and neck, soft tissue, and bone cancers with radiotherapy.
Her expertise includes adaptive radiotherapy and radiosurgery. She uses advanced radiation techniques to provide personalized, evidence-based care in a multidisciplinary, patient-centered setting.
Video Stories from Bookimed Patients
Reviews about Bookimed: Discover Patients' Insights
All reviewsShare this content
Anna Leonova
FAQ about Actinium-225 Therapy in Turkey
What is the safety profile and potential side effects of Actinium-225 therapy in Turkey?
Actinium-225 therapy in Turkey has a strong safety profile. Its localised alpha radiation destroys cancer cells while sparing healthy tissue. JCI-accredited departments manage the treatment using international protocols. These measures help control side effects like xerostomia and temporary blood count changes.
- Xerostomia management: Salivary gland cooling or protective protocols help reduce dry mouth.
- Haematological monitoring: Regular blood tests track temporary white cell or platelet drops after infusion.
- Renal protection: Specialised amino acid infusions and hydration help protect kidney function.
- Precision screening: Pre-treatment PSMA PET-CT scans help the tracer target only cancerous tumours.
Bookimed Expert Insight: Turkish centres like Anadolu Medical Center maintain high standards through their affiliation with Johns Hopkins Hospital. This partnership means patients receive Actinium-225 therapy based on American clinical protocols. This includes MAG-3 renal scintigraphy. This scan is a vital safety step that evaluates kidney drainage before treatment starts.
Who is considered a suitable candidate for Actinium-225 therapy in Turkey?
Suitable candidates for Actinium-225 therapy in Turkey include men with metastatic castration-resistant prostate cancer. Specialists also treat patients with neuroendocrine tumours. They prioritise those who have exhausted standard treatments like chemotherapy or Lutetium-177. Patients must also show high Prostate-Specific Membrane Antigen expression on diagnostic PET scans.
- Clinical diagnosis: Targets cancers resistant to hormone therapy and previous Lutetium-177 treatments.
- PET imaging: Requires Gallium-68 or DOTA PET scans to confirm high radiotracer uptake.
- Organ function: Patients must show healthy bone marrow and stable kidney function before starting.
- Treatment history: Often used when cases progress despite multiple rounds of chemotherapy.
Bookimed Expert Insight: Actinium-225 is not only for prostate cancer. Medical centres like Anadolu Medical Center also use it for neuroendocrine tumours. These clinics follow standards set by Johns Hopkins Medicine. They include MAG-3 renal scintigraphy in the first cycle. This scan protects kidney health by measuring how the body clears the isotope.
Patient Consensus: Patients value the multidisciplinary approach in Turkey. Nuclear medicine specialists like Dr Kezban Berberoglu coordinate the entire diagnostic and therapy workflow. The inclusion of VIP transfers and personal coordinators makes navigating hospital schedules much easier.
How does Actinium-225 therapy for cancer work and what is its mechanism of action?
Actinium-225 therapy treats advanced cancers using targeted alpha therapy. It links the radioactive isotope to molecules that find specific proteins on tumours. Once bound, it releases high-energy alpha particles that shatter cancer DNA. This process saves surrounding healthy tissue due to its microscopic destructive range.
- Selective targeting: Molecules like PSMA or DOTA find specific proteins common on cancer surfaces.
- DNA shattering: Alpha particles cause double-strand breaks that cells find nearly impossible to repair.
- Short range: Radiation travels only 50–80 micrometres. This protects healthy organs next to the tumour.
- Oxygen independent: Physical force kills treatment-resistant, low-oxygen tumours that often survive traditional radiation.
Bookimed Expert Insight: Anadolu Medical Center uses its Johns Hopkins affiliation to maintain strict nuclear medicine protocols. Specialists like Professor Kezban Berberoglu often use MAG-3 renal scintigraphy before the first cycle. This confirms kidney function is strong enough to process the treatment safely. This extra diagnostic step is common in high-volume Turkish oncology centres.
Patient Consensus: Patients in Turkey find the therapy carries tumour-seeking molecules to multiple cancer sites at once. Precise imaging like PSMA PET scans confirms exactly where the radiopharmaceutical will bind before treatment.
What are the primary clinical differences between Actinium-225 and Lutetium-177 treatments?
Actinium-225 and Lutetium-177 differ fundamentally in radiation type and tissue penetration. Actinium-225 uses alpha particles to deliver energy over 1–10 cells. This causes irreparable DNA damage. Lutetium-177 uses beta particles to travel up to 2 millimetres. This makes it better for debulking large tumours via cross-fire effects.
- Radiation power: Actinium-225 delivers 400 times the destructive energy density of Lutetium-177 particles.
- DNA impact: Alpha particles cause catastrophic double-strand breaks that cancer cells cannot repair.
- Clinical indication: Lutetium-177 treats bulky tumours; Actinium-225 targets microscopic clusters and resistant disease.
- Side effect trade-off: Actinium-225 carries a higher risk of persistent dry mouth (xerostomia) than Lutetium.
Bookimed Expert Insight: Data shows Turkish centres like Anadolu Medical Center increasingly use tandem therapy protocols. Combining both isotopes allows doctors to debulk large tumours with Lutetium. They then use Actinium to clear resistant micro-metastases. This sequential approach helps manage toxicity while achieving deep Prostate-Specific Antigen (PSA) reductions.
Patient Consensus: Patients often describe Actinium-225 as a harder-hitting salvage therapy used when Lutetium-177 stops working. They highlight that while Turkey offers potent responses, managing dry mouth remains a primary concern during recovery.
What is the expected travel timeline and medical protocol for Actinium-225 therapy in Turkey?
Actinium-225 therapy in Turkey requires a 4–7 day stay per treatment cycle. The medical protocol involves pre-treatment diagnostic imaging and a 1-hour intravenous infusion. Patients also follow short-term radiation safety precautions. Most undergo multiple cycles spaced 4–8 weeks apart at JCI-accredited centres like Anadolu Medical Center.
- Treatment cycles: Patients generally require 3–6 cycles for metastatic prostate or neuroendocrine cancers.
- Clinical stay: Plan for 4–7 days in Istanbul for consultation, imaging, and administration.
- Pre-treatment workup: Standard protocols include PSMA PET scans and MAG-3 renal scintigraphy for safety.
- Travel criteria: Patients must carry hospital discharge notes to clear sensitive airport radiation scanners.
Bookimed Expert Insight: Actinium-225 in Turkey is often managed as a short-stay procedure. This differs from many radiotherapy options that require lengthy hospitalisation. Centres like Anadolu Medical Center follow Johns Hopkins Medicine standards. These allow patients to fly home within 48 hours. This is possible because alpha particles have a short travel distance. They pose minimal risk to others during travel.
Patient Consensus: Patients found that providing imaging and blood results early sped up eligibility reviews. Most recommend booking extra days in Istanbul for baseline tests and post-treatment monitoring.
Where are the major clinics providing Actinium-225 therapy in Turkey located?
Major hospitals providing Actinium-225 therapy in Turkey are mostly in Istanbul. These facilities specialise in targeted alpha-radionuclide radiation for prostate and neuroendocrine cancers. Many hold Joint Commission International (JCI) accreditation and maintain global medical affiliations.
- Istanbul metropolitan area: Primary clusters in districts like Gebze, Sisli, Besiktas, and Kadikoy.
- Anadolu Medical Center: Located in Gebze with Johns Hopkins Medicine affiliation and JCI accreditation.
- Memorial Sisli Hospital: Situated in central Sisli and was Turkey's first JCI-certified hospital.
- Specialised nuclear units: Facilities often feature dedicated wings for molecular imaging and tandem therapies.
Bookimed Expert Insight: Anadolu Medical Center in Istanbul offers pricing from A$31,700 for neuroendocrine cancer therapy. This clinic is a standout because it holds ESMO accreditation. It also follows Johns Hopkins standards. This level of European and American clinical oversight provides a reliable benchmark for Australians.
Patient Consensus: Patients find the coordination in Istanbul remarkably efficient. Specialised nuclear medicine teams handle everything from initial PSMA PET scans to treatment. They also help by organising airport transfers.















